Diagnose Early Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Diagnose Early's estimated annual revenue is currently $5.9M per year.(i)
  • Diagnose Early's estimated revenue per employee is $155,000

Employee Data

  • Diagnose Early has 38 Employees.(i)
  • Diagnose Early grew their employee count by 36% last year.

Diagnose Early's People

NameTitleEmail/Phone
1
Founder & Board DirectorsReveal Email/Phone
2
Chief Information OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Diagnose Early?

Founded by a Nobel Prize-winning team including Stanford M.D./Ph.D., Nobel Laureate, and a Harvard Business School/UW Madison Engineer. We are commercializing diagnostics for Cancer, Neurological, and Infectious Diseases, and are in clinical trials at Stanford University. The Diagnose Early team has patented a COVID-19 Acuity test titled D.E.C.A. that uses amino acid biomarkers found in breath to accurately and non-invasively predict the clinical course of each patient and therefore guide treatment.

keywords:N/A

N/A

Total Funding

38

Number of Employees

$5.9M

Revenue (est)

36%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.2M38-5%N/A
#2
$10M386%N/A
#3
$6.9M3865%N/A
#4
$4.4M3819%N/A
#5
$9.9M38N/AN/A